CureVac (NASDAQ:CVAC) Shares Sold by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale lessened its stake in shares of CureVac (NASDAQ:CVAC) by 31.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 85,642 shares of the company’s stock after selling 40,000 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in CureVac were worth $363,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. lifted its stake in shares of CureVac by 95.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,738 shares of the company’s stock worth $39,000 after acquiring an additional 2,804 shares in the last quarter. Swiss National Bank lifted its stake in shares of CureVac by 1.8% in the third quarter. Swiss National Bank now owns 221,406 shares of the company’s stock worth $1,462,000 after acquiring an additional 3,925 shares in the last quarter. Pathstone Family Office LLC acquired a new position in shares of CureVac in the third quarter worth about $89,000. Deutsche Bank AG lifted its stake in shares of CureVac by 5.1% in the third quarter. Deutsche Bank AG now owns 72,510 shares of the company’s stock worth $495,000 after acquiring an additional 3,491 shares in the last quarter. Finally, Federated Hermes Inc. lifted its stake in shares of CureVac by 33.3% in the third quarter. Federated Hermes Inc. now owns 40,000 shares of the company’s stock worth $273,000 after acquiring an additional 10,000 shares in the last quarter. Institutional investors and hedge funds own 17.26% of the company’s stock.

CureVac Price Performance

Shares of CureVac stock opened at $2.67 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.56 and a quick ratio of 3.41. CureVac has a fifty-two week low of $2.54 and a fifty-two week high of $12.36. The business has a 50-day moving average price of $3.22 and a 200 day moving average price of $4.33.

Wall Street Analysts Forecast Growth

Separately, Guggenheim reissued a “neutral” rating on shares of CureVac in a report on Friday, April 5th.

About CureVac

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza.